Justice Department, Drug Enforcement Administration Briefing 2026-09-08
Estimated reading time: 5 minutes
Title: 1. Mark Allen, D.D.S.; Rescission of Final Agency Action and Withdrawal of Order To Show Cause
Sub: Justice Department, Drug Enforcement Administration
Title: 2. Bulk Manufacturer of Controlled Substances Application: Irvine Labs, Inc.
Sub: Justice Department, Drug Enforcement Administration
Content: Irvine Labs, Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Title: 3. Importer of Controlled Substances Application: Fisher Clinical Services, Inc.
Sub: Justice Department, Drug Enforcement Administration
Content: Fisher Clinical Services, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
Title: 4. Importer of Controlled Substances Application: Cambrex High Point, Inc.
Sub: Justice Department, Drug Enforcement Administration
Content: Cambrex High Point, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Title: 5. Importer of Controlled Substances Application: Fresenius Kabi USA, LLC
Sub: Justice Department, Drug Enforcement Administration
Content: Fresenius Kabi USA, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
Title: 6. Stephen Bossenberry, M.D.; Decision and Order
Sub: Justice Department, Drug Enforcement Administration
Title: 7. Importer of Controlled Substances Application: AndersonBrecon, Inc DBA PCI Pharma Services
Sub: Justice Department, Drug Enforcement Administration
Content: AndersonBrecon, Inc DBA PCI Pharma Services has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Legal Disclaimer
This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.
